- Home
- FATE
as 04-01-2025 4:00pm EST
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 108.2M | IPO Year: | 2013 |
| Target Price: | $5.50 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Hold | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.75 - $7.35 | Next Earning Date: | 03-05-2025 |
| Revenue: | $13,631,000 | Revenue Growth: | -78.55% |
| Revenue Growth (this year): | -72.22% | Revenue Growth (next year): | -22.66% |
Stock Insider Trading Activity of Fate Therapeutics Inc. (FATE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| TAHL CINDY | FATE | See Remarks | Jan 10 '25 | Sell | $1.55 | 5,654 | $8,763.70 | 336,707 | |
| Valamehr Bahram | FATE | President and CEO | Jan 10 '25 | Sell | $1.54 | 8,705 | $13,405.70 | 349,364 | |
| Bressi Jerome Charles | FATE | See Remarks | Jan 10 '25 | Sell | $1.55 | 5,980 | $9,269.00 | 270,203 |
Latest Fate Therapeutics Inc. News
FATE Breaking Stock News: Dive into FATE Ticker-Specific Updates for Smart Investing
Simply Wall St.
24 days ago
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target
Zacks
a month ago
FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus
Zacks
a month ago
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
Associated Press Finance
a month ago
Fate Therapeutics: Q4 Earnings Snapshot
GlobeNewswire
a month ago
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
GlobeNewswire
a month ago
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Zacks
a month ago
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks
a month ago
Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know
Compare FATE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FATE Fate Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.